natgillin/translations-raw huggingface dataset:
A compound of formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: 
Spoj formule I: zo OOH ili njegova farmaceutski prihvatljiva sol ili solvat, naznačeno time, da:
The nucleic acid molecule of claim 5, wherein the VL domain is linked to a control protein and the VH domain is linked to the Fc. 
Molekula nukleinske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time, da je VL povezan s oznakom te time, da je VH povezan s Fc.
or an activated derivative thereof with the amine NHR4R5 wherein NR4R5 has the meaning defined in formula (1) under standard conditions for preparing amides from a carboxylic acid or a mixed anhydride thereof and an amine HNR4R5. 
(11) ili njenog aktiviranog derivata s aminom NHR4Rs, gdje NRARs znači kao što je definirano za formulu (1), u standardnim uvjetima dobivanja amida iz karboksilne kiseline ili njenog miješanog anhidrida i amina HNR4ARs.
Compounding of the masterbatch with the base TPE is a well known conventional procedure. 
Miješanje glavne šarže s osnovnim TPE je dobro poznat konvencionalni postupak.
maintaining a device database comprising profile information relating to said electric devices in said geographical area; 
održavanja baze podataka o uređajima (606) koja sadrži informacije o profilu koje se odnose na navedene električne uređaje (208) u navedenom geografskom području;
In another embodiment, the compound of formula (I) or a tautomer thereof is in the form of the free base. 
Pripravak prema zahtjevu 1 naznačen time da je najmanje 98% u obliku S-enantiomera.
A conditional replication defective cytomegalovirus (CMV) with destabilized IE1/2 and UL51 proteins, wherein the genome of the CMV is represented by SEQ ID NO: 14. 
Citomegalovirus (CMV) s uvjetno defektnom replikacijom sa destabiliziranim IE1/2 i ULSI proteinima, naznačen time što je genom CMV predstavljen sa SEQ ID NO: 14.
Thus, the compound according to the invention is preferably 2-(2-methyl-5-nitroimidazol-1-yl)ethyl (S)-2-(2-fluorobiphenyl-4-yl)propionate. 
Spoj prema jednom od zahtjeva 1 do 7, naznačen time što je to 2(2-metil-5-nitroimidazol-1-iljetil (S)-2-(2- fluorobifenil-4-il)propionat.
Compounds of the structure (AV) can be prepared from 3-ethoxy-cyclopentenone by treatment with dialkyloxalate such as di-tert-butyl oxalate or diethyloxalate in the presence of a non-nucleophilic base such as LDA or LHMDS in a solvent such as THF to give the ketoester (AM). 
(af Spojevi strukture (AV) se mogu pripremiti iz 3-etoksi-ciklopentenona tretiranjem s dialkiloksalatom poput di-terc-butil oksalata ili dietiloksalata u prisutnosti ne-nukleofilne baze poput LDA ili LHMDS u otapalu poput THF da bi se dobio keto-ester (AM).
A speargun as claimed in claim 1, wherein the return means consist of at least one pulley (13, 13I, 13II, 13III, 13IV) at the head (10) and/or the body of the speargun. 
Podvodna puška u skladu sa zahtjevom 1, pri čemu sredstvo za vraćanje obuhvaća najmanje jednu remenicu (13, 13', 137, 13", 137) na glavi (10) i /ili na trupu podvodne puške.
Methods of Producing Antibodies of the Invention 
Datum objave europske prijave patenta:
An aerosol or spray package comprising the pharmaceutical composition of claim 1. 
Aerosolno ili sprejno pakiranje, naznačeno time što sadrži farmaceutski pripravak u skladu s patentnim zahtjevom
The method of claim 99, wherein said insulin is bolus insulin, basal insulin, or an analogue thereof. 
navedeni inzulin je bolus inzulin, bazni inzulin ili njegov analog.
A device for vacuum wound therapy comprising: 
Uređaj za vakuumsku terapiju rana koji sadrži:
R represents one or more halogen atoms, preferably chlorine; said process comprising the following steps according to scheme 1: reacting a compound of formula (II) wherein X is defined as above and X' is chlorine, bromine, iodine or a triflate group (CF3SO3) with a compound of formula (III) wherein R is defined as above to form a compound of formula (IV); 
X jest fluor, te predstavlja jedan ili više atoma halogena, naznačen time da rečeni postupak obuhvaća sljedeće korake: (1) reakcija spoja formule (II), X' DO X (ID u kojoj je X gore definiran, a X' je odabran iz sljedeće skupine: klor, brom, jod te triflatna skupina (CF3SO:), sa spojem formule (III)
The fusion protein of claim 5, comprising an amino acid sequence that has at least 99% sequence identity to the amino acid sequence of AE912-hGH-AE144 or AE912-hGH-AE288 as shown in Table 36. 
AE912-hGH-AE144 ili AE912-hGH-AE288, koje su prikazane u Tablici 36. Fuzijski protein prema zahtjevu 5, naznačen time, da obuhvaća aminokiselinsku sekvencu koja ima najmanje 99% identiteta od aminokiselinske sekvence od
It is to be noted that in this preferred purification process, IL-18BP does not bind to the cation exchange resin, and thus the flow-through of this column is used for further processing. 
Treba se shvatiti da u ovom poželjnom koraku za pročišćavanje, IL-18BP se ne vezuje za kationski izmjenjivač pa se zbog toga eluat iz ove kolone dalje procesira.
European patent application 0378881 . 
Broj europske prijave patenta:
10 mL 20% citric acid was added and the reaction mixture was stirred for 30 minutes. 
Dodaje se 10 mL 20% limunske kiseline i reakcijska smjesa se miješa još 30 minuta.
Furthermore, mixtures of the aforementioned acids can be used. Typically the antagonist of M3 muscarinic receptors is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide. 
Kombinacija u skladu s patentnim zahtjevom 1, naznačena time, da je antagonist M3 muskarinskih receptora (b) spoj (3R)-1-fenetil-3-(2H-ksanten-9-karboniloksi)-1-azoniabiciklo [2.2.2 Joktan bromid.
The method according to claim 1, wherein 0% to 99% of the solids segregated in the filter are re-channelled into the fluidized bed reactor. 
Postupak prema jednom od Zahtjeva 1 do 4, naznačen time, što se od 20% do 99% čvrstih čestica koje su odvojene u filteru vraća nazad u reaktor (3) s fluidiziranim slojem.
Ch#N, wherein, in order to generate the data pseudo-streams 3 c, 3 d, the splitting means 4 will: 
ChiHN), gdje, da bi se generirali navedeni pseudo-tokovi (3c,3d) podataka, navedena sredstva (4) za razdvajanje će:
Such bypass channels 49 allows the base part 5 and the base unit 3 according to this embodiment to be used as described above for the embodiment shown in figs. 2a-c . 
Takovi spojni kanali 49 omogućuju da se osnovni dio 5 i osnovna jedinica 3 prema ovoj izvedbi izuma upotrijebe kao što je gore opisano za izvedbu prikazanu na slikama 2a-c.
water is added to the solution obtained in step a) in order to obtain a solution of said melphalan flufenamide hydrochloride (J1) in a concentration of 0.2-3.0 mg/ml; 
voda se dodaje otopini dobivenoj u koraku a) kako bi se dobila otopina spomenutog melfalan flufenamid hidroklorida (J1) u koncentraciji od 0,2-3,0 mg / ml;
Also, the repeated use of high loads causes premature wear in the latch keys and groove. 
Isto tako, učestalo korištenje visokih opterećenja izaziva prijevremeno habanje u zasunu i šupljini.
Figure 2 is an XRPD spectrum of pellets produced in Example 1 measured after 1 month storage in a plastic container with desiccant at 40°C and 75% RH; 
Slika2 je XRPD spektar peleta dobivenih u Primjeru 1 izmjeren nakon mjesec dana skladištenja u plastičnom spremniku uz desikans, na 40 *C, uz 75 % relativne vlage;
After that, cells were treated with 800 pM of peroxynitrite for an overnight. 
Nakon toga, stanice su obrađene preko noći s 800 uM peroksinitrita.
The piercer 11 in the embodiment shown in Figures 2a-2c is made as an integrated part of the base unit 3. 
Bušilo 11 u izvedbi prikazanoj na slikama 2a-2c je izrađeno kao integralni dio osnovne jedinice 3.
is C(1-2)alkyl, CH2CH2OCH3, or OCH3; or A1 and A2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of: 
A? je Ca-alkil, CH2CH2OCHL, ili OCH; ili AA? mogu se uzeti zajedno s njihovim dušikom na koji su spojeni da se dobije prsten koji je odabran iz skupine koja sadrži:
wrapping the naked collation film around the ordered configuration of individually wrapped packages to form a film tube with overlapping edges; 
omatanju golog kolacijskog filma oko uređene konfiguracije pojedinačno umotanih pakiranja kako bi se načinilo filmsku cijev s preklopljenim rubovima;
wherein said ring is optionally substituted with up to three substituents independently selected from the group consisting of F, CF3, CH3, —CN, and CH2OH; 
S den pri čemu spomenuti prsten je po potrebi supstituiran sa do tri supstituenata nezavisno izabranih iz grupe koja obuhvaća F, CF3, CH, -CN, i CHLOH;
wherein the processor determines the value of the flow rate referent to the active combination of circuits that make up the electronic circuit. 
sustav (S3) za obradu podataka određuje vrijednost brzine toka koja se odnosi na aktivnu kombinaciju kruga (S1.3.1) koji sačinjavaju električni krug (S1.3).
applying an inverse primary transform to the primary transform coefficients to generate an output signal representing the respective channel in the respective audio block, wherein 
(C) primjenu inverzne primarne transformacije na primarne transformacijske koeficijente da se dobije izlazni signal koji predstavlja odgovarajući kanal u odgovarajućem audio bloku.
In a further embodiment of the first aspect of the present invention, the above-mentioned compound of formula (3): 
NO, olJ/ O, priprema slijedećim korakom A3: pri čemu je spoj s formulom (3):
In another aspect the invention also provides compositions further comprising an antipsychotic or antidepressant agent. 
Prema drugom aspektu, izum opisuje kompozicije koje se nadalje sadrže antipsihotičke ili antidepresivne agense.
However, due to the relatively high costs of obtaining fragrances from natural substances, the modern trend is to use synthetically prepared fragrances, particularly in high-volume products. 
Međutim, zbog relativno visokih troškova dobivanja mirisa iz prirodnih tvari, moderni trend je upotreba sintetski dobivenih mirisa, naročito u masovnim proizvodima.
mixing the at least two conjugates prepared in (1), to give a composition that includes the common carrier in an unconjugated form, wherein the concentration of the unconjugated common carrier is less than 10 µg/ml. 
HR P20090607 TI daju sastav koji uključuje zajednički nosač u nekonjugiranom obliku, gdje je koncentracija nekonjugiranog zajedničkog nosača manja od 10 ug/ml. .
The composition for use according to claim 23, wherein therapeutically effective amount of crenolanib or a salt thereof is administered orally, intravenously, or intraperitoneally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje oralno, intravenozno ili intraperitonealno.
the proximal end of the second fragment is located within a second repeat portion; and wherein the first fragment and the second fragment are separated by less than or exactly 5 amino acids in the primary structure, wherein the polypeptide elicits antibodies that neutralise toxin A and toxin B and wherein the first repeat portion and the second repeat portion have greater than 50% sequence identity to one another. 
(iv) proksimalni kraj drugog fragmenta se nalazi unutar drugog ponavljanog dijela; i gdje su prvi fragment i drugi fragment razdvojeni s manje od ili točno 5 aminokiselina u primarnoj strukturi, gdje polipeptid dovodi do pojave protutijela koja neutraliziraju toksin A i toksin B, te gdje su prvi ponavljani dio i drugi ponavljani dio imaju između sebe više od 50% istovjetnog slijeda.
to 40 unrearranged human λ immunoglobulin light chain variable region gene segments (hVλ) and at least one human Jλ (hJλ) gene segment which are operably linked to a mouse Ck gene at an endogenous mouse k immunoglobulin light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained; and a human Vk-Jk intergenic nucleic acid sequence located between the 12 to 40 human immunoglobulin light chain variable region gene segments and the at least one human Jλ nucleic acid sequence; 
Miš prema patentnom zahtjevu 1, naznačen time, što miš sadrži: od 12 do 40 nepreuređenih segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca A (hV2) i najmanje jedan humani segment gena JA (hJA); 1 humanu međugensku sekvencu nukleinske kiseline VK-JK smještenu između 12 do 40 segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca i najmanje jedne sekvence nukleinske kiseline JA.
The composition as in claim 23 or 24 for use in said method further comprising, prior to administering, diagnosing the eye of the mammal with an eye disorder that is suitably treated with chronic administration of a therapeutic agent. The composition as in claim 25 wherein the eye disorder is elevated intraocular pressure. 
Pripravak za upotrebu u postupku prema patentnom zahtjevu 14, naznačen time, da postupak nadalje sadrži, prije primjene, dijagnosticiranje oka sisavca s poremećajem oka koji je prikladno tretiran s kroničnim davanjem terapeutskog sredstva, gdje je poželjno poremećaj oka povišen intraokularni tlak.
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, wherein: ring A is independently phenyl or a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O and S; wherein said phenyl and heteroaryl are substituted with 0-1 R6 and 0-2 R7; 
R2-a R (I) ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, solvat ili hidrat tog spoja, gdje: prsten A je nezavisno 5- do 6-očlani heteroaril koji sadrži ugljikove atome i 1-4 heteroatoma odabrana od N, NR", O i S; gdje spomenuti heteroaril je supstituiran sa 0-1 R*10-2R';
Subsequent rehydration of the alkene (II) will then give predominantly or exclusively a single enantiomer of the cis-dihydrotetrabenazine (VI). 
Rehidriranje alkena (II) neposredno nakon toga će dati predominantno ili potpuno pojedinačni cnantiomcr cis-dihidrotetrabenazina (VI).
A peptide according to any one of claims 1 to 5, a nucleic acid or expression vector according to claim 6, a host cell according to claim 7, a CTL according to claim 11 or 12, or an antibody according to claim 13 for use as a medicament in the treatment of cancer, such as, for example, gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za uporabu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega.
cervical carcinoma), adenocarcinomas, herpes virus-induced tumours (e.g. 
karcinom cerviksa), adenokarcinomi, tumori uzrokovani herpes virusima (npr.
The procedure as claimed in any of claims 9 to 11, where the quantity of carob gum employed in step (c) is at least 1.0%. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 8 do 10, naznačen time što je upotrijebljena količina rogačeve gume u koraku (c) najmanje 1,0 %.
After 3 hours, additional DCC (13.0g) in toluene (140mL) was added. 
Nakon 3 sata bio je dodan dodatni DCC (13.0 g) u toluenu (140 mL).
A compound according to claim 1 or 2 for use in the treatment or prophylaxis of pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors. 
5. = Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da se upotrebljava u liječenju ili prevenciji boli, kod ateroskleroze, regulacije koštane mase, upala, ishemije, reperfuzijskih ozljeda, sistemske fibroze, jetrene fibroze, fibroze pluća, fibroze bubrega, kronične nefropatije bubrežnog presatka, kongestivnog zatajenja srca, infarkta miokarda, sistemske skleroze, glomerulonefropatije, toplinskih ozljeda, opeklina, hipertrofičnih ožiljaka, keloida, febrilnog gingivitisa, ciroze jetre ili tumora.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
Reel (20) according to claim 7, wherein said strip of material (S) is heat-sealing on both sides. 
Namotaj (20) u skladu s patentnim zahtjevom 5, pri čemu je navedena traka materijala (S) za toplinsko lijepljenje na obje strane.
and R9 taken together with nitrogen to which they are attached form a non-aromatic heterocyclic ring containing 2 - 6 carbon atoms which is: 
i R9, uzeti zajedno s dušikom na kojeg su vezani, tvore nearomatski heterociklički prsten s 2-6 atoma ugljika koji je:
The animal of Clause 1, wherein the first nucleotide sequence is located at the endogenous non-human MHC I locus, the second nucleotide sequence is located at the endogenous non-human MHC II a locus, and the third nucleotide sequence is located at the endogenous non-human MHC II B locus. 
Životinja prema zahtjevu 1, naznačena time, da se prva nukleotidna sekvenca nalazi na endogenom ne-humanom MHC-I-lokusu, druga nukleotidna sekvenca se nalazi na endogenom ne-humanom MHC-II-a-lokusu, a treća nukleotidna sekvenca se nalazi na endogenom ne-humanom MHC-II-f-lokusu.
The base station device of claims 1 or 2, wherein the random access response comprises the timing deviation information further not used for the mobile station device to perform uplink timing alignment in the uplink synchronous status. 
Uređaj mobilne stanice (50) prema zahtjevu 1 ili 2, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena koja je uključena u primljenom odgovoru slučajnog pristupa (S02).
a body for receiving a substance source, the body having a mouthpiece; a dispenser cap comprising a hollow body having a lower open end engageable with the body, and an upper open end for receiving a cap closure device for closing the upper open end, the upper open end comprising an engageable portion; and 
poklopac (91) dispenzera koji sadrži šuplje tijelo koje ima donji otvoreni kraj koji može da se angažira sa tijelom, i gornji otvoreni kraj za prijem uređaja za zatvaranje poklopca za zatvaranje gornjeg otvorenog kraja, pri čemu gornji otvoreni kraj sadrži dio koji se može angažirati; i uređaj (120) za zatvaranje poklopca, koji sadrži: gornji dio (121) za zatvaranje poklopca za angažiranje sa gornjim otvorenim krajem dispenzera da bi se zatvorio gornji otvoreni kraj poklopca dispenzera;
the heavy chain variable domain of SEQ ID NO:208 and the light chain variable domain of SEQ ID NO:207; or 
varijabilnu domenu jakog lanca koja sadrži HVR1-H1, HVR-H2 i HVR-H3 od SEQ ID NO:164-166 i varijabilnu domenu slabog lanca koja sadrži HVR-L1, HVR-L2 i HVR-L3 od SEQ ID NO:156-158; ili
Process according to claim 1, wherein at least one of R3 and R4 is a hydrogen atom, in particular R3 and R4 are both hydrogen atoms. 
Postupak prema zahtjevu 1, naznačen time da najmanje jedan od R; i R, je vodikov atom, naročito da R3 i Ry su oba atomi vodika.
The device (7) according to claim 1, wherein said connection element (11) comprises: 
Naprava (7) u skladu s patentnim zahtjevom 4, naznačena time što navedeni nosač (10) i navedeni spojni element (11) ima:
The integrated circuit according to claim 1, wherein the first aggregation level value is 1 or 2 and the second aggregation level value is 4 or 8. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 21 da je druga vrijednost razine agregacije 4 ili 6.
The injector of claims 1 or claim 2, wherein the ion source is adapted to produce about a 9 A negative ion beam. 
Injektor prema zahtjevu 1 ili 2, naznačen time, da je ionski izvor prilagođen za proizvodnju negativne ionske zrake od oko 9 A.
A is a connecting group connecting L1 to the cell binding agent (CBA); 
A je spojna skupina koja spaja L' na sredstvo za vezanje stanice (CBA);
Re and Re are the same or different, and are selected from -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH2-CH2-O)n-Rk, wherein Rk is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g., -NHR101) or tertiary amino (-NR101R102) group or a 5- or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R101 and R102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms; preferably, R101 and R102 are each independently a linear or branched alkyl having 1 to 6 carbon atoms; 
su Re i Re- isti ili različiti i odabrani su od -H, linearnog, razgranatog ili cikličnog alkila, alkenila ili alkinila koji ima od 1 do 10 ugljikovih atoma ili -(CH2-CH2-O)n-Rk, pri čemu je Rk -H, linearni, razgranati ciklični alkil koji ima 1 do 6 ugljikovih atoma, koji izborno nosi sekundarnu amino (npr., -NHR101) ili tercijarnu amino (-NR101R102) skupinu ili 5-člani ili 6-člani dušik koji ima heterocikl, kao što je piperidin ili morfolin, pri čemu su R101 i R102 svaki neovisno linearni, razgranati, ili ciklični alkil, alkenil ili alkinil koji ima 1 do 10 ugljikovih atoma; poželjno, R101 i R102 su svaki neovisno linearni ili razgranati alkil koji ima 1 do 6 ugljikovih atoma;
The apparatus of claim 1 wherein at least one of the attachment points is accessible through the hollow pipe connection and at least one attachment point is located on the upper surface of the body. The apparatus of claim 3 wherein the least one point attachment accessible through the hollow pipe connection is located on a cross member located inside the interior of the body. 
Sklop u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što je najmanje jedno od mjesta spajanja (231) dostupno kroz šuplju cijevnu vezu (236), a najmanje jedno mjesto spajanja (230) se nalazi na gornjoj površini tijela (235).
The method as claimed in claims 2 or 3, wherein the paper (2) is a thin raw paper with a weight of about 40 - 60 g/m2. 
Metoda u skladu sa patentnim zahtjevima 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 60 g/m2.